Skip to main content
Erschienen in: Journal of Neurology 2/2019

16.06.2018 | Review

Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects

verfasst von: Joaquin A. Vizcarra, Miguel Situ-Kcomt, Carlo Alberto Artusi, Andrew P. Duker, Leonardo Lopiano, Michael S. Okun, Alberto J. Espay, Aristide Merola

Erschienen in: Journal of Neurology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

While subthalamic nucleus deep brain stimulation (STN-DBS) and levodopa improve motor symptoms in Parkinson disease (PD) to a similar magnitude, their combined effect remains unclear. We sought to evaluate whether STN-DBS and levodopa yield differential effects on motor outcomes, dyskinesia, and activities of daily living (ADL) when combined compared to when administered alone.

Methods

We conducted a meta-analysis of all studies reporting motor, dyskinesia, and ADL outcomes after bilateral STN-DBS in PD with presurgical Unified Parkinson’s Disease Rating Scale (UPDRS-III) in Medication-OFF and Medication-ON states and postsurgical assessments in four conditions: Stimulation-ON/Medication-ON, Stimulation-ON/Medication-OFF, Stimulation-OFF/Medication-ON, and Stimulation-OFF/Medication-OFF. Dyskinesia duration (UPDRS item 32) and ADL (UPDRS-II) were compared between high and low postsurgical levodopa equivalent daily dose (LEDD) reduction. Random-effects meta-analyses using generic-inverse variance were conducted. Confidence in outcomes effect sizes was assessed.

Results

Twelve studies were included (n = 401 patients). Stimulation-ON/Medication-ON was associated with an UPDRS-III improvement of − 35.7 points [95% confidence interval, − 40.4, − 31.0] compared with Stimulation-OFF/Medication-OFF, − 11.2 points [− 14.0, − 8.4] compared with Stimulation-OFF/Medication-ON, and − 9.5 points [− 11.0, − 8.0] compared to Stimulation-ON/Medication-OFF within 5 years. The difference was maintained beyond 5 years by − 28.6 [− 32.8, − 24.4], − 8.1 [− 10.2, − 5.9], and − 8.0 [− 10.3, − 5.6], respectively. No difference was observed between Stimulation-ON/Medication-OFF and Stimulation-OFF/Medication-ON within and beyond 5 years. Dyskinesia duration and ADL outcomes were similar in high vs. low postsurgical LEDD reduction.

Conclusion

Subthalamic nucleus deep brain stimulation and levodopa independently lessened motor severity in PD to a similar magnitude, but their combined effect was greater than either treatment alone, suggesting therapeutic synergism.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rowland NC, Sammartino F, Lozano AM (2017) Advances in surgery for movement disorders. Mov Disord 32:5–10CrossRefPubMed Rowland NC, Sammartino F, Lozano AM (2017) Advances in surgery for movement disorders. Mov Disord 32:5–10CrossRefPubMed
2.
Zurück zum Zitat Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S et al (2005) Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 128:2240–2249CrossRefPubMed Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S et al (2005) Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 128:2240–2249CrossRefPubMed
3.
Zurück zum Zitat Schupbach M, Gargiulo M, Welter ML, Mallet L, Behar C, Houeto JL et al (2006) Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 66:1811–1816CrossRefPubMed Schupbach M, Gargiulo M, Welter ML, Mallet L, Behar C, Houeto JL et al (2006) Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 66:1811–1816CrossRefPubMed
4.
Zurück zum Zitat Okun MS, Wu SS, Fayad S, Ward H, Bowers D, Rosado C et al (2014) Acute and chronic mood and apathy outcomes from a randomized study of unilateral STN and GPi DBS. PLoS One 9:1–16CrossRef Okun MS, Wu SS, Fayad S, Ward H, Bowers D, Rosado C et al (2014) Acute and chronic mood and apathy outcomes from a randomized study of unilateral STN and GPi DBS. PLoS One 9:1–16CrossRef
5.
Zurück zum Zitat Zibetti M, Merola A, Rizzi L, Ricchi V, Angrisano S, Azzaro C et al (2011) Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. Mov Disord 26:2327–2334CrossRefPubMed Zibetti M, Merola A, Rizzi L, Ricchi V, Angrisano S, Azzaro C et al (2011) Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. Mov Disord 26:2327–2334CrossRefPubMed
6.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269 W64.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269 W64.CrossRef
7.
Zurück zum Zitat Stroup DF (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:2008–2012CrossRef Stroup DF (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:2008–2012CrossRef
8.
Zurück zum Zitat Defer G-L, Widner H, Marié R-M, Rémy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584CrossRefPubMed Defer G-L, Widner H, Marié R-M, Rémy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584CrossRefPubMed
10.
Zurück zum Zitat Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 342:d4002CrossRef Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 342:d4002CrossRef
11.
Zurück zum Zitat The GRADE Working Group (2013) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach The GRADE Working Group (2013) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach
12.
Zurück zum Zitat Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.handbook.cochrane.org Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.​handbook.​cochrane.​org
13.
Zurück zum Zitat Østergaard K, Sunde NA (2006) Evolution of Parkinson’s disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 21:624–631CrossRefPubMed Østergaard K, Sunde NA (2006) Evolution of Parkinson’s disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 21:624–631CrossRefPubMed
14.
Zurück zum Zitat Ząbek M, Sobstyl M, Koziara H, Kądziołka B, Mossakowski Z, Dierzęcki S (2010) Bilateral subthalamic nucleus stimulation in the treatment of advanced Parkinson’s disease. Five years’ personal experience. Neurol Neurochir Pol 44:3–12CrossRef Ząbek M, Sobstyl M, Koziara H, Kądziołka B, Mossakowski Z, Dierzęcki S (2010) Bilateral subthalamic nucleus stimulation in the treatment of advanced Parkinson’s disease. Five years’ personal experience. Neurol Neurochir Pol 44:3–12CrossRef
15.
Zurück zum Zitat Visser-Vandewalle V, Van Der Linden C, Temel Y, Celik H, Ackermans L, Spincemaille G et al (2005) Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Relat Disord 11:157–165CrossRefPubMed Visser-Vandewalle V, Van Der Linden C, Temel Y, Celik H, Ackermans L, Spincemaille G et al (2005) Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Relat Disord 11:157–165CrossRefPubMed
16.
Zurück zum Zitat Merola A, Romagnolo A, Bernardini A, Rizzi L, Artusi CA, Lanotte M et al (2015) Earlier versus later subthalamic deep brain stimulation in Parkinson’s disease. Parkinsonism Relat Disord 21:972–975CrossRefPubMed Merola A, Romagnolo A, Bernardini A, Rizzi L, Artusi CA, Lanotte M et al (2015) Earlier versus later subthalamic deep brain stimulation in Parkinson’s disease. Parkinsonism Relat Disord 21:972–975CrossRefPubMed
17.
Zurück zum Zitat Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA et al (2011) Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 134:2074–2084CrossRefPubMed Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA et al (2011) Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 134:2074–2084CrossRefPubMed
18.
Zurück zum Zitat Moro E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann J et al (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 25:578–586CrossRefPubMed Moro E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann J et al (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 25:578–586CrossRefPubMed
19.
Zurück zum Zitat Castrioto A, Lozano A, Poon Y-Y, Lang AE, Fallis M, Moro E (2011) Ten-year outcome of subthalamic stimulation in Parkinson disease. Arch Neurol 68:1550–1556CrossRefPubMed Castrioto A, Lozano A, Poon Y-Y, Lang AE, Fallis M, Moro E (2011) Ten-year outcome of subthalamic stimulation in Parkinson disease. Arch Neurol 68:1550–1556CrossRefPubMed
20.
Zurück zum Zitat Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YYW et al (2007) Levodopa response in long-term bilateral subthalamic stimulation for Parkinson’s disease. Mov Disord 22:990–997CrossRefPubMed Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YYW et al (2007) Levodopa response in long-term bilateral subthalamic stimulation for Parkinson’s disease. Mov Disord 22:990–997CrossRefPubMed
21.
Zurück zum Zitat Schupbach WMM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM et al (2005) Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 76:1640–1644CrossRefPubMedPubMedCentral Schupbach WMM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM et al (2005) Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 76:1640–1644CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Simonin C, Tir M, Devos D, Kreisler A, Dujardin K, Salleron J et al (2009) Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon. J Neurol 256:1736–1741CrossRefPubMed Simonin C, Tir M, Devos D, Kreisler A, Dujardin K, Salleron J et al (2009) Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon. J Neurol 256:1736–1741CrossRefPubMed
23.
Zurück zum Zitat Horváth K, Aschermann Z, Ács P, Deli G, Janszky J, Komoly S et al (2015) Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord 21:1421–1426CrossRefPubMed Horváth K, Aschermann Z, Ács P, Deli G, Janszky J, Komoly S et al (2015) Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord 21:1421–1426CrossRefPubMed
24.
Zurück zum Zitat Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676CrossRefPubMed Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676CrossRefPubMed
25.
Zurück zum Zitat Rizzone MG, Fasano A, Daniele A, Zibetti M, Merola A, Rizzi L et al (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord 20:376–381CrossRefPubMed Rizzone MG, Fasano A, Daniele A, Zibetti M, Merola A, Rizzi L et al (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord 20:376–381CrossRefPubMed
26.
Zurück zum Zitat Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A et al (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 136:1568–1577CrossRefPubMed Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A et al (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 136:1568–1577CrossRefPubMed
27.
Zurück zum Zitat Stemper B, Beric A, Welsch G, Haendl T, Sterio D, Hilz MJ (2006) Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 67:1781–1785CrossRefPubMed Stemper B, Beric A, Welsch G, Haendl T, Sterio D, Hilz MJ (2006) Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 67:1781–1785CrossRefPubMed
28.
Zurück zum Zitat Joyce J, Ryoo H, Beach T, Caviness J, Stacy M, Gurevich E et al (2002) Loss of response to levodopa in Parkinson’s disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 955:138–152CrossRefPubMed Joyce J, Ryoo H, Beach T, Caviness J, Stacy M, Gurevich E et al (2002) Loss of response to levodopa in Parkinson’s disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 955:138–152CrossRefPubMed
29.
Zurück zum Zitat Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW (2006) Striatal dopaminergic neurons are lost with Parkinson’s disease progression. Mov Disord 21:2208–2211CrossRefPubMed Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW (2006) Striatal dopaminergic neurons are lost with Parkinson’s disease progression. Mov Disord 21:2208–2211CrossRefPubMed
30.
Zurück zum Zitat Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43CrossRefPubMed Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43CrossRefPubMed
Metadaten
Titel
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects
verfasst von
Joaquin A. Vizcarra
Miguel Situ-Kcomt
Carlo Alberto Artusi
Andrew P. Duker
Leonardo Lopiano
Michael S. Okun
Alberto J. Espay
Aristide Merola
Publikationsdatum
16.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 2/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-8936-2

Weitere Artikel der Ausgabe 2/2019

Journal of Neurology 2/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.